KR102173587B1 - 피로의 치료 또는 예방 방법 - Google Patents

피로의 치료 또는 예방 방법 Download PDF

Info

Publication number
KR102173587B1
KR102173587B1 KR1020197026173A KR20197026173A KR102173587B1 KR 102173587 B1 KR102173587 B1 KR 102173587B1 KR 1020197026173 A KR1020197026173 A KR 1020197026173A KR 20197026173 A KR20197026173 A KR 20197026173A KR 102173587 B1 KR102173587 B1 KR 102173587B1
Authority
KR
South Korea
Prior art keywords
compound
fatigue
sleep
group
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197026173A
Other languages
English (en)
Korean (ko)
Other versions
KR20190105675A (ko
Inventor
모이세 에이. 카이라
개리 브림
스테판 이. 버츠
수잔 마리 멜닉
던칸 테일러
Original Assignee
에스케이바이오팜 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 에스케이바이오팜 주식회사 filed Critical 에스케이바이오팜 주식회사
Publication of KR20190105675A publication Critical patent/KR20190105675A/ko
Application granted granted Critical
Publication of KR102173587B1 publication Critical patent/KR102173587B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A61K31/175—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine having the group, >N—C(O)—N=N— or, e.g. carbonohydrazides, carbazones, semicarbazides, semicarbazones; Thioanalogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/20—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020197026173A 2009-06-22 2010-06-21 피로의 치료 또는 예방 방법 Active KR102173587B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21908209P 2009-06-22 2009-06-22
US61/219,082 2009-06-22
PCT/US2010/039313 WO2011005473A2 (en) 2009-06-22 2010-06-21 Methods for treating or preventing fatigue

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020177020249A Division KR102021075B1 (ko) 2009-06-22 2010-06-21 피로의 치료 또는 예방 방법

Publications (2)

Publication Number Publication Date
KR20190105675A KR20190105675A (ko) 2019-09-17
KR102173587B1 true KR102173587B1 (ko) 2020-11-04

Family

ID=43429751

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020197026173A Active KR102173587B1 (ko) 2009-06-22 2010-06-21 피로의 치료 또는 예방 방법
KR1020127001795A Ceased KR20120098578A (ko) 2009-06-22 2010-06-21 피로의 치료 또는 예방 방법
KR1020177020249A Active KR102021075B1 (ko) 2009-06-22 2010-06-21 피로의 치료 또는 예방 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020127001795A Ceased KR20120098578A (ko) 2009-06-22 2010-06-21 피로의 치료 또는 예방 방법
KR1020177020249A Active KR102021075B1 (ko) 2009-06-22 2010-06-21 피로의 치료 또는 예방 방법

Country Status (12)

Country Link
US (5) US8741950B2 (enExample)
EP (1) EP2445490B1 (enExample)
JP (3) JP6095366B2 (enExample)
KR (3) KR102173587B1 (enExample)
CN (2) CN106727486A (enExample)
AU (1) AU2010270971B2 (enExample)
BR (1) BRPI1015233A2 (enExample)
IN (1) IN2012DN00624A (enExample)
MX (1) MX2012000034A (enExample)
RU (1) RU2567801C2 (enExample)
TW (1) TWI453014B (enExample)
WO (1) WO2011005473A2 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0613697A2 (pt) 2005-06-08 2011-01-25 Sk Holdings Co Ltd tratamento de distúrbios de sono-vigìlia
KR102173587B1 (ko) * 2009-06-22 2020-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법
EP2496227B1 (en) * 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US9060994B2 (en) 2011-12-21 2015-06-23 Inno Biosciences, S.p.A. Combination therapy with interferon and andrographolides for Multiple Sclerosis
WO2014164969A1 (en) 2013-03-13 2014-10-09 Aerial Biopharma, Llc Treatment of cataplexy
KR20160030955A (ko) * 2013-07-12 2016-03-21 에스케이바이오팜 주식회사 금연의 촉진
WO2015010014A1 (en) * 2013-07-18 2015-01-22 Jazz Pharmaceuticals International Iii Limited Treatment for obesity
CA2928675C (en) * 2013-11-08 2023-09-05 Legacy Healthcare Ltd Method for the management of cancer and cancer treatment-related comorbidities
US10888542B2 (en) 2014-02-28 2021-01-12 Sk Biopharmaceuticals Co., Ltd. Aminocarbonylcarbamate compounds
TWI698415B (zh) 2014-02-28 2020-07-11 南韓商愛思開生物製藥股份有限公司 胺基羰基胺基甲酸酯化合物
SG11201901998WA (en) 2016-09-06 2019-04-29 Jazz Pharmaceuticals International Iii Ltd Solvate form of (r)-2-amino-3-phenylpropyl carbamate
US10195151B2 (en) * 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
EP3523275B1 (en) * 2016-10-06 2023-09-27 Axsome Malta Ltd. Carbamoyl phenylalaninol compounds for medical use
CN110139905B (zh) * 2016-12-30 2021-09-28 株式会社东进世美肯 涂层组合物及由此制备的薄膜
WO2018222954A1 (en) 2017-06-02 2018-12-06 Jazz Pharmaceuticals International Iii Limited Methods and compositions for treating excessive sleepiness
EP3661911A4 (en) 2017-07-31 2021-04-14 Jazz Pharmaceuticals Ireland Limited CARBAMOYL-PHENYLALANINOL ANALOGS AND USES THEREOF
JP7428480B2 (ja) * 2019-06-06 2024-02-06 雪印メグミルク株式会社 睡眠改善用組成物及び組成物を含む食品、医薬品、飼料
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
KR102390194B1 (ko) * 2020-08-03 2022-04-25 셀라이온바이오메드 주식회사 페닐알킬 카바메이트 화합물을 포함하는 Kca3.1채널 매개질환 치료용 조성물
AU2022390879A1 (en) * 2021-11-16 2024-06-13 Axsome Malta Ltd. Methods and compositions for treating cognitive impairment
WO2025006965A1 (en) 2023-06-29 2025-01-02 Axsome Therapeutics, Inc. Methods of administering solriamfetol to lactating women

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996007637A1 (en) 1994-09-09 1996-03-14 Yukong Limited Novel phenylalkylaminoalcohol carbamates and process for preparing the same
WO1996024577A1 (en) 1995-02-11 1996-08-15 Yukong Limited O-carbamoyl-(d)-phenylalanilol compounds and process for preparing the same
WO1998015526A1 (en) 1996-10-10 1998-04-16 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
WO2006050037A1 (en) 2004-10-28 2006-05-11 Sk Corporation Adjunctive therapy for depression
KR102021075B1 (ko) 2009-06-22 2019-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ285762B6 (cs) 1993-06-10 1999-11-17 Eli Lilly And Company Farmaceutický prostředek vhodný pro prevenci dávení a zvracení a pro ošetřování sexuální dysfunkce savců a jeho použití
US5756817C1 (en) 1995-02-11 2001-04-17 Sk Corp O-carbamoyl-phenylananinol compounds their pharmaceutically useful salts and process for preparing the same
KR0173863B1 (ko) * 1995-04-10 1999-04-01 조규향 페닐에 치환체가 있는 o-카바모일-페닐알라닌올 화합물과 그의 약제학적으로 유용한 염 및 이들의 제조방법
WO1998015626A2 (en) 1996-10-08 1998-04-16 Institute Of Child Health Mutant ciita molecule and uses thereof
AU4674797A (en) 1996-10-22 1998-05-15 Ortho Pharmaceutical Corporation Phenylalaninol derivatives for the treatment of central nervous system disorders
US20040229951A1 (en) 2003-05-15 2004-11-18 Arthur Vanmoor Method of treating fatigue by enhancing the effectiveness of the human immune system
RU2267319C2 (ru) * 2003-07-15 2006-01-10 Общество с ограниченной ответственностью "Интер-Кэр" Фармацевтическая композиция и способ лечения синдрома хронической усталости с ее использованием
US20050080268A1 (en) 2003-10-08 2005-04-14 Yong-Moon Choi Process of preparing O-carbamoyl compounds in the presence of active amine group
BRPI0613697A2 (pt) 2005-06-08 2011-01-25 Sk Holdings Co Ltd tratamento de distúrbios de sono-vigìlia
CA2612672C (en) 2005-06-22 2014-10-14 Janssen Pharmaceutica, N.V. Treatment for sexual dysfunction
CN101272776B (zh) 2005-07-26 2012-10-03 詹森药业有限公司 氨基甲酸酯在制备治疗物质滥用相关疾病药物中的用途
CN101557804A (zh) 2006-10-13 2009-10-14 詹森药业有限公司 氨基甲酸苯基烷基氨基酯组合物
US8232315B2 (en) 2009-06-26 2012-07-31 Sk Biopharmaceuticals Co., Ltd. Methods for treating drug addiction and improving addiction-related behavior
EP2496227B1 (en) 2009-11-06 2019-05-22 SK Biopharmaceuticals Co., Ltd. Methods for treating fibromyalgia syndrome
KR101783632B1 (ko) 2009-11-06 2017-10-10 에스케이바이오팜 주식회사 주의력 결핍/과잉행동 장애(ａｄｈｄ)의 치료 방법
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
US8623913B2 (en) 2010-06-30 2014-01-07 Sk Biopharmaceuticals Co., Ltd. Methods for treating restless legs syndrome
WO2014164969A1 (en) * 2013-03-13 2014-10-09 Aerial Biopharma, Llc Treatment of cataplexy
JP6215740B2 (ja) * 2014-03-14 2017-10-18 本田技研工業株式会社 部品の締結構造

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996007637A1 (en) 1994-09-09 1996-03-14 Yukong Limited Novel phenylalkylaminoalcohol carbamates and process for preparing the same
WO1996024577A1 (en) 1995-02-11 1996-08-15 Yukong Limited O-carbamoyl-(d)-phenylalanilol compounds and process for preparing the same
WO1998015526A1 (en) 1996-10-10 1998-04-16 Sk Corporation O-carbamoyl-phenylalaninol compounds, their pharmaceutically useful salts and process for preparing the same
WO2006050037A1 (en) 2004-10-28 2006-05-11 Sk Corporation Adjunctive therapy for depression
KR102021075B1 (ko) 2009-06-22 2019-11-04 에스케이바이오팜 주식회사 피로의 치료 또는 예방 방법

Also Published As

Publication number Publication date
AU2010270971B2 (en) 2015-08-20
US20180263950A1 (en) 2018-09-20
JP2015214564A (ja) 2015-12-03
US8741950B2 (en) 2014-06-03
MX2012000034A (es) 2012-02-21
EP2445490A2 (en) 2012-05-02
WO2011005473A9 (en) 2011-05-12
US20120142769A1 (en) 2012-06-07
US9464041B2 (en) 2016-10-11
KR20120098578A (ko) 2012-09-05
AU2010270971A1 (en) 2012-01-19
EP2445490A4 (en) 2019-10-23
IN2012DN00624A (enExample) 2015-06-12
US9999609B2 (en) 2018-06-19
JP2018188450A (ja) 2018-11-29
KR20170086710A (ko) 2017-07-26
KR102021075B1 (ko) 2019-11-04
JP2012530779A (ja) 2012-12-06
WO2011005473A2 (en) 2011-01-13
CN106727486A (zh) 2017-05-31
TWI453014B (zh) 2014-09-21
CN102481274A (zh) 2012-05-30
RU2567801C2 (ru) 2015-11-10
US20200061017A1 (en) 2020-02-27
US10507192B2 (en) 2019-12-17
EP2445490B1 (en) 2023-02-08
CA2765463A1 (en) 2011-01-13
JP6368285B2 (ja) 2018-08-01
BRPI1015233A2 (pt) 2018-02-20
CA2765463C (en) 2018-10-09
JP6095366B2 (ja) 2017-03-15
US20170000756A1 (en) 2017-01-05
TW201105320A (en) 2011-02-16
RU2012101947A (ru) 2013-07-27
US20140243406A1 (en) 2014-08-28
KR20190105675A (ko) 2019-09-17

Similar Documents

Publication Publication Date Title
KR102173587B1 (ko) 피로의 치료 또는 예방 방법
US9248098B2 (en) Treating or preventing pain using spicamycin derivatives
US20030143282A1 (en) Adenosine A3 receptor agonist
CA2765463E (en) Methods for treating or preventing fatigue
AU2014203896B2 (en) Compositions and methods for treating cutaneous T cell lymphoma
HK1171657A (en) Methods for treating or preventing fatigue
HK1234314A1 (en) Methods for treating or preventing fatigue
HK1217165B (en) Compositions and methods for treating cutaneous t cell lymphoma

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6